Serum CA 15-3 is increased in pulmonary fibrosis

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 26, Issue 1, 2009, Pages 54-63

  Ricci, Alberto ^a   Mariotta, S ^a   Bronzetti, E ^a   Bruno, P ^a   Vismara, L ^b   De Dominicis, C ^b   Lagana B ^c   Paone, G ^a   Mura, M ^d   Rogliani, P ^d   Mastrangelo, M ^e   Sciacchitano, S ^a   Saltini, Cesare ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Radiologia   (Italy)

^c Univetsity of Rome   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e I Div/IV Rip5   (Italy)

Author keywords

CA 15 3; ELISA; Idiopathic interstitial pneumonias; Immunohistochemistry; Sarcoidosis; Systemic sclerosis

Indexed keywords

CA 15-3 ANTIGEN; CARBON MONOXIDE;

ADULT; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROSING ALVEOLITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG FIBROBLAST; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOIDOSIS; SYSTEMIC SCLEROSIS; TOTAL LUNG CAPACITY;

EID: 70349254236     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. American Thoracic Society/European Respiratory Society: International multidisciplinary consensus classification of idiopathic interstitial pneumonias: general principles and recommendations. Am J Respir Crit Care Med 2002; 165: 277-304
2. Lynch JP 3rd, Saggar R, Weigt SS, Zisman DA, White ES: Usual interstitial pneumonia. Semin Respir Crit Care Med. 2006; 27: 634-651
3. Hunninghake GW, Garrett KC, Richerson HB, et al: Pathogenesis of the granulomatous lung disease. Am Rev Res Dir Dis 1984; 130: 476-496
4. Michell-DN, Scadding JG: Sarcoidosis. Am Rev Respir Dis 1976; 110: 774-802.
5. Aladesanmi OA: Sarcoidosis: an update for the primary care physician. Med Gen Med. 2004; 6: 7
6. Mitchell DN, Scadding JG, Heard BE, Hinson KF: Sarcoidosis: histopathological definition and clinical diagnosis. J Clin Pathol 1977; 30: 395-408.
7. Varga J, Abraham D: Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007; 117: 557-567 (Pubitemid 46348510)
8. McCarthy DS, Baragar FD, Dhingra S: The lungs in systemic sclerosis (scleroderma):a review and new information. Semin Arthritis Rheum 1988; 17: 2018-2033
9. Hilkens J, Ligtenberg MJ, Vos HL, Litvinov SV: Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci 1992; 17: 359-363
10. Offner GD, Troxler RF: Heterogeneity of high-molecular-weight human salivary mucins. Adv Dent Res 2000; 14: 69-75.
11. Ho SB, Niehans GA, Lyftogt C, et al: Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993; 53: 641-651 (Pubitemid 23059449)
12. Ihn H, Asano Y, Kubo M, et al: Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease. Rheumatology. 2002; 41: 1268-1272 (Pubitemid 35363801)
13. Kallioniemi OP, Oksa H, Aaran RK, Hietanen T, Lehtinen M, Koivula T: Serum CA 15-3 assay in the diagnosis and follow-up of breast cancer. Br J Cancer 1988; 58: 213-215 (Pubitemid 18225606)
14. Wong RC, Klingberg S, Wilson R: CA15-3 and cancer associated serum antigen assays are alternatives to the KL-6 assay for measuring serum MUC-1 levels in patients with interstitial lung disease associated with polymyositis/dermatomyositis. J Rheumatol 2002; 29: 2021-2022 (Pubitemid 34988719)
15. Okada M., Suzuki K., Nakanishi T. Nakashima M: Serum levels of KL-6 are positively correlated with those of CA15-3 in patients with interstitial pneumonia associated with collagen diseases Respirology. 2006; 11: 509-510
16. Iwata Y, Wada T, Furuichi K, et al: Serum levels of KL-6 reflect disease activity of interstitial pneumonia associated with ANCA-related vasculitis. Intern Med. 2001; 40: 1093-1097 (Pubitemid 33133717)
17. Kohno N, Yokoyama A, Kondo K: KL-6 as a serum marker for amiodarone-induced pulmonary toxicity. Intern Med. 2000; 39: 1004-1005 (Pubitemid 32052320)
18. Eskelinen M, Kataja V, Hämäläinen E, Kosma VM, Penttilä I, Alhava E: Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer. Anticancer Research 1997; 17: 1231-1234 (Pubitemid 27182444)
19. Lopez La, Del Villar V, Ulla M, et al: Prevalence of abnormal levels of serum tumour markers in elderly people. Age and Ageing 1996; 25: 45-50. (Pubitemid 26037292)
20. Wong RC, Klingberg S, Wilson R: CA15-3 and cancer associated serum antigen assays are alternatives to the KL-6 assay for measuring serum MUC-1 levels in patients with interstitial lung disease associated with polymyositis/dermatomyositis. J Rheumatol 2002; 29: 2021-2022 (Pubitemid 34988719)
21. Yokoyama A, Kohno N, Hamada H, et al: Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158: 1680-1684 (Pubitemid 28536637)
22. Rosas IO, Richards TJ, Konishi K, et al: MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008; 29: e93. (Pubitemid 351649261)
23. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M: New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989; 96: 68-73.
24. Kohno N, Awaya Y, Oyama T, et al: KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis. 1993; 148: 637-642 (Pubitemid 23263772)
25. Kohno N: Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. J Med Invest 1999; 46: 151-158
26. Goto K, Kodama T, Sekine I, et al: Serum levels of KL-6 are useful biomarkers for severe radiation pneumonitis. Lung Cancer 2001; 34: 141-148 (Pubitemid 32824134)
27. Hirasawa Y, Kohno N, Yokoyama A, Inoue Y, Abe M, Hiwada K: KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts. Am J Respir Cell Mol Biol. 1997; 17: 501-507 (Pubitemid 127500983)
28. Kohno N, Kyoizumi S, Tanabe M, et al. Detection of a circulating tumor-associated antigen with a murine monoclonal antibody, LISA 101, selected by reversed indirect enzyme-linked immunosorbent assay. Cancer Res 1989; 15: 3412-3419 (Pubitemid 19162160)
29. Chilosi M, Poletti V, Zamo A, et al: Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J P Pathol 2003; 162: 1495-1502 (Pubitemid 36512831)
30. Okubo T, Hogan BL: Hyperactive Wnt signaling changes the developmental potential of embryonic lung endoderm. J Biol 2004; 3: 11. (Pubitemid 39044761)
31. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2: 442-454
32. Königshoff M, Balsara N, Pfaff EM, et al: Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS ONE. 2008; 14: e2142. (Pubitemid 352025166)
33. Huang L, Ren J, Chen D, Li Y, Kharbanda S, Kufe D: MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. Cancer Biol Ther. 2003; 2: 702-706
34. Lynch DA, Godwin DJ, Safrin S, et al: Idiopathic Pulmonary Fibrosis Study Group. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005; 172: 488-493
35. Drent M, De Vries J, Lenters M, et al: Sarcoidosis: assessment of disease severity using HRCT. Eur Radiol 2003; 13: 2462-2471 (Pubitemid 37407478)
36. Ooi GC, Mok MY, Tsang KW, et al: Interstitial lung disease in systemic sclerosis. Acta Radiol 2003; 44: 258-264
37. Mogulkoc N, Brutsche MH, Bishop PW, et al: Greater Manchester Pulmonary Fibrosis Consortium. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med 2001; 164: 103-108